A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia

Hidetoshi Shibaki; Takehisa Chimoto; Tooru Nakabayashi; Yoshiro Ishii; Matsumi Tosaka; Hajime Watanabe; Sokichi Onodera; Tetsuo Shimizu; Nobuhiro Sasaki; Yuji Ikeda; Jutaro Shimomura; Hiroyuki Tokunaka; Akira Ujiie; Masahide Shinohara; Takashi Takahori; Yoichi Gocho; Fimiei Kondo; Fumio Nagahama; Akira Saitosh; Kiyofumi Ishikawa; Akira Suzuki; Yomei Hiraga; Kohki Kikuchi; Tomoko Yamamato; Akio Hirayama; Soichiro Uehara; Mikiya Satoh; Masumi Tomisawa; Kyuichiro Sekine; Tohru Natsuisaka; Masahiko Yamagishi; Hiroshi Takagi; Katsuo Suzuki; Mikihiko Tango; Einosuke Odagaki; Yoshiaki Ichishima; Morokuni Abe; Yoshio Kurihara; Choei Itoh; Keisuke Takeuchi; Tatsuya Ishizuka; Osamu Yajima; Tsuyoshi Kikuiri; Tadashii Murakami; Shinichi Oshima; Kazuo Takebe; Katsuhiro Okamoto; Syuichiro Yoshida; Yoshihiro Kumasaka; Tatsuro Irie; Mitsuo Nakamura; Tadeshi Miyasawa; Masashi Yoneda; Naoyoshi Masaki; Toyochi Tamura; Kohzo Kurahashi; Yuichi Hirai; Hitoshi Yashiro; Norihiko Hirota; Masashi Tamura; Takashi Itoh; Shigeki Mori; Fumitoshi Yamauchi; Kiyoshi Omuro; Hiroshi Ishikawa; Takashi Tsuruya; Hiroshi Kuramitsu; Kotaro Itakura; Yasuyuki Suzuki; Kazutoshi Gomi; Katsuyoshi Moriya; Nobuhisa Satoh; Mikio Matsui; Norimi Kometani; Masao Satoh; Yoshikatsu Nemoto; Kiyoshi Kawamorita; Noboru Asabu; Akio Ebina; Seiichi Aonuma; Tsukasa Yoshida; Hiromi Yaoi; Masaaki Itasawa; Syuji Chiba; Saburo Shindoh; Kiichi Kaishio; Hidetaka Satoh; Kazuo Satoh; Kiyoshi Konno; Kohtaro Oizumi; Akira Watanabe; Hiroyuki Nakai; Kohsaku Nagai; Teruo Hasuike; Izumi Hayashi; Tsugushi Ito; Shigemi Kohsaka; Shigeo Takisawa; Kenkichi Shikanai; Yuzuru Matsumoto

doi:10.11553/antibiotics1968b.39.853

A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia

Hidetoshi Shibaki, Takehisa Chimoto, Tooru Nakabayashi, Yoshiro Ishii, Matsumi Tosaka, Hajime Watanabe, Sokichi Onodera, Tetsuo Shimizu, Nobuhiro Sasaki, Yuji Ikeda, Jutaro Shimomura, Hiroyuki Tokunaka, Akira Ujiie, Masahide Shinohara, Takashi Takahori, Yoichi Gocho, Fimiei Kondo, Fumio Nagahama, Akira Saitosh, Kiyofumi IshikawaAkira Suzuki, Yomei Hiraga, Kohki Kikuchi, Tomoko Yamamato, Akio Hirayama, Soichiro Uehara, Mikiya Satoh, Masumi Tomisawa, Kyuichiro Sekine, Tohru Natsuisaka, Masahiko Yamagishi, Hiroshi Takagi, Katsuo Suzuki, Mikihiko Tango, Einosuke Odagaki, Yoshiaki Ichishima, Morokuni Abe, Yoshio Kurihara, Choei Itoh, Keisuke Takeuchi, Tatsuya Ishizuka, Osamu Yajima, Tsuyoshi Kikuiri, Tadashii Murakami, Shinichi Oshima, Kazuo Takebe, Katsuhiro Okamoto, Syuichiro Yoshida, Yoshihiro Kumasaka, Tatsuro Irie, Mitsuo Nakamura, Tadeshi Miyasawa, Masashi Yoneda, Naoyoshi Masaki, Toyochi Tamura, Kohzo Kurahashi, Yuichi Hirai, Hitoshi Yashiro, Norihiko Hirota, Masashi Tamura, Takashi Itoh, Shigeki Mori, Fumitoshi Yamauchi, Kiyoshi Omuro, Hiroshi Ishikawa, Takashi Tsuruya, Hiroshi Kuramitsu, Kotaro Itakura, Yasuyuki Suzuki, Kazutoshi Gomi, Katsuyoshi Moriya, Nobuhisa Satoh, Mikio Matsui, Norimi Kometani, Masao Satoh, Yoshikatsu Nemoto, Kiyoshi Kawamorita, Noboru Asabu, Akio Ebina, Seiichi Aonuma, Tsukasa Yoshida, Hiromi Yaoi, Masaaki Itasawa, Syuji Chiba, Saburo Shindoh, Kiichi Kaishio, Hidetaka Satoh, Kazuo Satoh, Kiyoshi Konno, Kohtaro Oizumi, Akira Watanabe, Hiroyuki Nakai, Kohsaku Nagai, Teruo Hasuike, Izumi Hayashi, Tsugushi Ito, Shigemi Kohsaka, Shigeo Takisawa, Kenkichi Shikanai, Yuzuru Matsumoto

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The S6472 is a 4: 6 mixture of 2 types of granules of cefaclor (CCL) coated with different films; one type of granules is soluble at low pH's and absorbed in the stomach while the other type is soluble at high pH's and absorbed in the intestine. The difference in absorption sites makes it possible to maintain blood concentrations of the drug at clinically efficient levels for a longer period of time compared with ordinary CCL. The efficacy, safety and usefulness of S6472 in the treatment of bacterial pneumonia was compared with those of ordinary CCL and of amoxicillin (AMPC) by the blind method. The patients entered in this trial were those who had bacterial pneumonia or lung abscess and were 16 years or above of age. The S6472 was given orally for 14 days at a daily dose of 1,500 mg (750 mg each after breakfast and supper), CCL was given at a daily dose of 1,500 mg (500 mg each after every meal), and AMPC at 2,000 mg (500 mg each after every meal and at the bedtime). To make the study blind, placeboes were matched with the test drug so that patients in every treatment group took 4 doses per day. Out of a total of 195 patients thus treated, 179 patients (55 in S6472 group, 62 in CCL group and 62 in AMPC group) were adopted for the evaluation by committee members while 185 patients (58 in S6472 group, 63 in CCL group and 64 in AMPC group) by controllers. When clinical results of the 3 treatment groups were compared, no statistically significant differences were observed in efficacy rates (cure rates), incidences of side effects nor abnormal findings of laboratory tests. From these results of this trial, it is concluded that oral administration of 750 mg of S6472 twice a day (1,500 mg per day) is as effective and useful as that of 500 mg of ordinary CCL 3 times a day (1,500 mg per day) or 500 mg of AMPC 4 times a day (2,000 mg per day) in the treatment of bacterial pneumonia or lung abscess.

Original language	English
Pages (from-to)	853-886
Number of pages	34
Journal	The Japanese Journal of Antibiotics
Volume	39
Issue number	3
DOIs	https://doi.org/10.11553/antibiotics1968b.39.853
Publication status	Published - 1986 Mar
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.39.853

Cite this

Shibaki, H., Chimoto, T., Nakabayashi, T., Ishii, Y., Tosaka, M., Watanabe, H., Onodera, S., Shimizu, T., Sasaki, N., Ikeda, Y., Shimomura, J., Tokunaka, H., Ujiie, A., Shinohara, M., Takahori, T., Gocho, Y., Kondo, F., Nagahama, F., Saitosh, A., ... Matsumoto, Y. (1986). A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia. The Japanese Journal of Antibiotics, 39(3), 853-886. https://doi.org/10.11553/antibiotics1968b.39.853

Shibaki, H, Chimoto, T, Nakabayashi, T, Ishii, Y, Tosaka, M, Watanabe, H, Onodera, S, Shimizu, T, Sasaki, N, Ikeda, Y, Shimomura, J, Tokunaka, H, Ujiie, A, Shinohara, M, Takahori, T, Gocho, Y, Kondo, F, Nagahama, F, Saitosh, A, Ishikawa, K, Suzuki, A, Hiraga, Y, Kikuchi, K, Yamamato, T, Hirayama, A, Uehara, S, Satoh, M, Tomisawa, M, Sekine, K, Natsuisaka, T, Yamagishi, M, Takagi, H, Suzuki, K, Tango, M, Odagaki, E, Ichishima, Y, Abe, M, Kurihara, Y, Itoh, C, Takeuchi, K, Ishizuka, T, Yajima, O, Kikuiri, T, Murakami, T, Oshima, S, Takebe, K, Okamoto, K, Yoshida, S, Kumasaka, Y, Irie, T, Nakamura, M, Miyasawa, T, Yoneda, M, Masaki, N, Tamura, T, Kurahashi, K, Hirai, Y, Yashiro, H, Hirota, N, Tamura, M, Itoh, T, Mori, S, Yamauchi, F, Omuro, K, Ishikawa, H, Tsuruya, T, Kuramitsu, H, Itakura, K, Suzuki, Y, Gomi, K, Moriya, K, Satoh, N, Matsui, M, Kometani, N, Satoh, M, Nemoto, Y, Kawamorita, K, Asabu, N, Ebina, A, Aonuma, S, Yoshida, T, Yaoi, H, Itasawa, M, Chiba, S, Shindoh, S, Kaishio, K, Satoh, H, Satoh, K, Konno, K, Oizumi, K, Watanabe, A, Nakai, H, Nagai, K, Hasuike, T, Hayashi, I, Ito, T, Kohsaka, S, Takisawa, S, Shikanai, K & Matsumoto, Y 1986, 'A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia', The Japanese Journal of Antibiotics, vol. 39, no. 3, pp. 853-886. https://doi.org/10.11553/antibiotics1968b.39.853

@article{8b4f04cd8bc741b6b9ad72944dddf9d2,

title = "A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia",

abstract = "The S6472 is a 4: 6 mixture of 2 types of granules of cefaclor (CCL) coated with different films; one type of granules is soluble at low pH's and absorbed in the stomach while the other type is soluble at high pH's and absorbed in the intestine. The difference in absorption sites makes it possible to maintain blood concentrations of the drug at clinically efficient levels for a longer period of time compared with ordinary CCL. The efficacy, safety and usefulness of S6472 in the treatment of bacterial pneumonia was compared with those of ordinary CCL and of amoxicillin (AMPC) by the blind method. The patients entered in this trial were those who had bacterial pneumonia or lung abscess and were 16 years or above of age. The S6472 was given orally for 14 days at a daily dose of 1,500 mg (750 mg each after breakfast and supper), CCL was given at a daily dose of 1,500 mg (500 mg each after every meal), and AMPC at 2,000 mg (500 mg each after every meal and at the bedtime). To make the study blind, placeboes were matched with the test drug so that patients in every treatment group took 4 doses per day. Out of a total of 195 patients thus treated, 179 patients (55 in S6472 group, 62 in CCL group and 62 in AMPC group) were adopted for the evaluation by committee members while 185 patients (58 in S6472 group, 63 in CCL group and 64 in AMPC group) by controllers. When clinical results of the 3 treatment groups were compared, no statistically significant differences were observed in efficacy rates (cure rates), incidences of side effects nor abnormal findings of laboratory tests. From these results of this trial, it is concluded that oral administration of 750 mg of S6472 twice a day (1,500 mg per day) is as effective and useful as that of 500 mg of ordinary CCL 3 times a day (1,500 mg per day) or 500 mg of AMPC 4 times a day (2,000 mg per day) in the treatment of bacterial pneumonia or lung abscess.",

author = "Hidetoshi Shibaki and Takehisa Chimoto and Tooru Nakabayashi and Yoshiro Ishii and Matsumi Tosaka and Hajime Watanabe and Sokichi Onodera and Tetsuo Shimizu and Nobuhiro Sasaki and Yuji Ikeda and Jutaro Shimomura and Hiroyuki Tokunaka and Akira Ujiie and Masahide Shinohara and Takashi Takahori and Yoichi Gocho and Fimiei Kondo and Fumio Nagahama and Akira Saitosh and Kiyofumi Ishikawa and Akira Suzuki and Yomei Hiraga and Kohki Kikuchi and Tomoko Yamamato and Akio Hirayama and Soichiro Uehara and Mikiya Satoh and Masumi Tomisawa and Kyuichiro Sekine and Tohru Natsuisaka and Masahiko Yamagishi and Hiroshi Takagi and Katsuo Suzuki and Mikihiko Tango and Einosuke Odagaki and Yoshiaki Ichishima and Morokuni Abe and Yoshio Kurihara and Choei Itoh and Keisuke Takeuchi and Tatsuya Ishizuka and Osamu Yajima and Tsuyoshi Kikuiri and Tadashii Murakami and Shinichi Oshima and Kazuo Takebe and Katsuhiro Okamoto and Syuichiro Yoshida and Yoshihiro Kumasaka and Tatsuro Irie and Mitsuo Nakamura and Tadeshi Miyasawa and Masashi Yoneda and Naoyoshi Masaki and Toyochi Tamura and Kohzo Kurahashi and Yuichi Hirai and Hitoshi Yashiro and Norihiko Hirota and Masashi Tamura and Takashi Itoh and Shigeki Mori and Fumitoshi Yamauchi and Kiyoshi Omuro and Hiroshi Ishikawa and Takashi Tsuruya and Hiroshi Kuramitsu and Kotaro Itakura and Yasuyuki Suzuki and Kazutoshi Gomi and Katsuyoshi Moriya and Nobuhisa Satoh and Mikio Matsui and Norimi Kometani and Masao Satoh and Yoshikatsu Nemoto and Kiyoshi Kawamorita and Noboru Asabu and Akio Ebina and Seiichi Aonuma and Tsukasa Yoshida and Hiromi Yaoi and Masaaki Itasawa and Syuji Chiba and Saburo Shindoh and Kiichi Kaishio and Hidetaka Satoh and Kazuo Satoh and Kiyoshi Konno and Kohtaro Oizumi and Akira Watanabe and Hiroyuki Nakai and Kohsaku Nagai and Teruo Hasuike and Izumi Hayashi and Tsugushi Ito and Shigemi Kohsaka and Shigeo Takisawa and Kenkichi Shikanai and Yuzuru Matsumoto",

year = "1986",

month = mar,

doi = "10.11553/antibiotics1968b.39.853",

language = "English",

volume = "39",

pages = "853--886",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

number = "3",

}

TY - JOUR

T1 - A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia

AU - Shibaki, Hidetoshi

AU - Chimoto, Takehisa

AU - Nakabayashi, Tooru

AU - Ishii, Yoshiro

AU - Tosaka, Matsumi

AU - Watanabe, Hajime

AU - Onodera, Sokichi

AU - Shimizu, Tetsuo

AU - Sasaki, Nobuhiro

AU - Ikeda, Yuji

AU - Shimomura, Jutaro

AU - Tokunaka, Hiroyuki

AU - Ujiie, Akira

AU - Shinohara, Masahide

AU - Takahori, Takashi

AU - Gocho, Yoichi

AU - Kondo, Fimiei

AU - Nagahama, Fumio

AU - Saitosh, Akira

AU - Ishikawa, Kiyofumi

AU - Suzuki, Akira

AU - Hiraga, Yomei

AU - Kikuchi, Kohki

AU - Yamamato, Tomoko

AU - Hirayama, Akio

AU - Uehara, Soichiro

AU - Satoh, Mikiya

AU - Tomisawa, Masumi

AU - Sekine, Kyuichiro

AU - Natsuisaka, Tohru

AU - Yamagishi, Masahiko

AU - Takagi, Hiroshi

AU - Suzuki, Katsuo

AU - Tango, Mikihiko

AU - Odagaki, Einosuke

AU - Ichishima, Yoshiaki

AU - Abe, Morokuni

AU - Kurihara, Yoshio

AU - Itoh, Choei

AU - Takeuchi, Keisuke

AU - Ishizuka, Tatsuya

AU - Yajima, Osamu

AU - Kikuiri, Tsuyoshi

AU - Murakami, Tadashii

AU - Oshima, Shinichi

AU - Takebe, Kazuo

AU - Okamoto, Katsuhiro

AU - Yoshida, Syuichiro

AU - Kumasaka, Yoshihiro

AU - Irie, Tatsuro

AU - Nakamura, Mitsuo

AU - Miyasawa, Tadeshi

AU - Yoneda, Masashi

AU - Masaki, Naoyoshi

AU - Tamura, Toyochi

AU - Kurahashi, Kohzo

AU - Hirai, Yuichi

AU - Yashiro, Hitoshi

AU - Hirota, Norihiko

AU - Tamura, Masashi

AU - Itoh, Takashi

AU - Mori, Shigeki

AU - Yamauchi, Fumitoshi

AU - Omuro, Kiyoshi

AU - Ishikawa, Hiroshi

AU - Tsuruya, Takashi

AU - Kuramitsu, Hiroshi

AU - Itakura, Kotaro

AU - Suzuki, Yasuyuki

AU - Gomi, Kazutoshi

AU - Moriya, Katsuyoshi

AU - Satoh, Nobuhisa

AU - Matsui, Mikio

AU - Kometani, Norimi

AU - Satoh, Masao

AU - Nemoto, Yoshikatsu

AU - Kawamorita, Kiyoshi

AU - Asabu, Noboru

AU - Ebina, Akio

AU - Aonuma, Seiichi

AU - Yoshida, Tsukasa

AU - Yaoi, Hiromi

AU - Itasawa, Masaaki

AU - Chiba, Syuji

AU - Shindoh, Saburo

AU - Kaishio, Kiichi

AU - Satoh, Hidetaka

AU - Satoh, Kazuo

AU - Konno, Kiyoshi

AU - Oizumi, Kohtaro

AU - Watanabe, Akira

AU - Nakai, Hiroyuki

AU - Nagai, Kohsaku

AU - Hasuike, Teruo

AU - Hayashi, Izumi

AU - Ito, Tsugushi

AU - Kohsaka, Shigemi

AU - Takisawa, Shigeo

AU - Shikanai, Kenkichi

AU - Matsumoto, Yuzuru

PY - 1986/3

Y1 - 1986/3

N2 - The S6472 is a 4: 6 mixture of 2 types of granules of cefaclor (CCL) coated with different films; one type of granules is soluble at low pH's and absorbed in the stomach while the other type is soluble at high pH's and absorbed in the intestine. The difference in absorption sites makes it possible to maintain blood concentrations of the drug at clinically efficient levels for a longer period of time compared with ordinary CCL. The efficacy, safety and usefulness of S6472 in the treatment of bacterial pneumonia was compared with those of ordinary CCL and of amoxicillin (AMPC) by the blind method. The patients entered in this trial were those who had bacterial pneumonia or lung abscess and were 16 years or above of age. The S6472 was given orally for 14 days at a daily dose of 1,500 mg (750 mg each after breakfast and supper), CCL was given at a daily dose of 1,500 mg (500 mg each after every meal), and AMPC at 2,000 mg (500 mg each after every meal and at the bedtime). To make the study blind, placeboes were matched with the test drug so that patients in every treatment group took 4 doses per day. Out of a total of 195 patients thus treated, 179 patients (55 in S6472 group, 62 in CCL group and 62 in AMPC group) were adopted for the evaluation by committee members while 185 patients (58 in S6472 group, 63 in CCL group and 64 in AMPC group) by controllers. When clinical results of the 3 treatment groups were compared, no statistically significant differences were observed in efficacy rates (cure rates), incidences of side effects nor abnormal findings of laboratory tests. From these results of this trial, it is concluded that oral administration of 750 mg of S6472 twice a day (1,500 mg per day) is as effective and useful as that of 500 mg of ordinary CCL 3 times a day (1,500 mg per day) or 500 mg of AMPC 4 times a day (2,000 mg per day) in the treatment of bacterial pneumonia or lung abscess.

AB - The S6472 is a 4: 6 mixture of 2 types of granules of cefaclor (CCL) coated with different films; one type of granules is soluble at low pH's and absorbed in the stomach while the other type is soluble at high pH's and absorbed in the intestine. The difference in absorption sites makes it possible to maintain blood concentrations of the drug at clinically efficient levels for a longer period of time compared with ordinary CCL. The efficacy, safety and usefulness of S6472 in the treatment of bacterial pneumonia was compared with those of ordinary CCL and of amoxicillin (AMPC) by the blind method. The patients entered in this trial were those who had bacterial pneumonia or lung abscess and were 16 years or above of age. The S6472 was given orally for 14 days at a daily dose of 1,500 mg (750 mg each after breakfast and supper), CCL was given at a daily dose of 1,500 mg (500 mg each after every meal), and AMPC at 2,000 mg (500 mg each after every meal and at the bedtime). To make the study blind, placeboes were matched with the test drug so that patients in every treatment group took 4 doses per day. Out of a total of 195 patients thus treated, 179 patients (55 in S6472 group, 62 in CCL group and 62 in AMPC group) were adopted for the evaluation by committee members while 185 patients (58 in S6472 group, 63 in CCL group and 64 in AMPC group) by controllers. When clinical results of the 3 treatment groups were compared, no statistically significant differences were observed in efficacy rates (cure rates), incidences of side effects nor abnormal findings of laboratory tests. From these results of this trial, it is concluded that oral administration of 750 mg of S6472 twice a day (1,500 mg per day) is as effective and useful as that of 500 mg of ordinary CCL 3 times a day (1,500 mg per day) or 500 mg of AMPC 4 times a day (2,000 mg per day) in the treatment of bacterial pneumonia or lung abscess.

UR - http://www.scopus.com/inward/record.url?scp=0022460691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022460691&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.39.853

DO - 10.11553/antibiotics1968b.39.853

M3 - Article

C2 - 3525883

AN - SCOPUS:0022460691

VL - 39

SP - 853

EP - 886

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

SN - 0368-2781

IS - 3

ER -

A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this